Eurobio Scientific Société anonyme (EPA:ALERS)
France
· Delayed Price · Currency is EUR 23.00
-0.90 (-3.77%)
Apr 28, 2026, 3:16 PM CET
EPA:ALERS Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Other Revenue | - | -0 | - | - | - | Upgrade
|
| Revenue | 169 | 154.95 | 130.65 | 152.9 | 185.32 | Upgrade
|
| Revenue Growth (YoY) | 9.07% | 18.60% | -14.56% | -17.50% | -2.04% | Upgrade
|
| Cost of Revenue | 91.7 | 82.99 | 73.16 | 81.66 | 85.91 | Upgrade
|
| Gross Profit | 77.3 | 71.95 | 57.49 | 71.24 | 99.41 | Upgrade
|
| Selling, General & Admin | 53 | 38.86 | 33.52 | 31 | 24.5 | Upgrade
|
| Research & Development | 4.6 | 4.65 | 5.91 | 3.47 | - | Upgrade
|
| Amortization of Goodwill & Intangibles | 8.9 | 8.52 | 7.92 | 5.9 | 4.79 | Upgrade
|
| Operating Expenses | 66.5 | 52.02 | 47.35 | 40.37 | 29.29 | Upgrade
|
| Operating Income | 10.8 | 19.93 | 10.14 | 30.87 | 70.12 | Upgrade
|
| Interest Expense | -2.9 | -4.13 | -4.36 | -1.26 | -0.41 | Upgrade
|
| Interest & Investment Income | - | 1.48 | 1.12 | 0.04 | - | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0.69 | 0.75 | 0.67 | 0.36 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.1 | -3.71 | 0.77 | 0.04 | -0.05 | Upgrade
|
| EBT Excluding Unusual Items | 7.8 | 14.26 | 8.42 | 30.35 | 70.01 | Upgrade
|
| Merger & Restructuring Charges | - | -6.6 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | 0.23 | Upgrade
|
| Other Unusual Items | - | -1.38 | -1.45 | -0.67 | 1.08 | Upgrade
|
| Pretax Income | 7.8 | 6.28 | 6.98 | 29.68 | 71.31 | Upgrade
|
| Income Tax Expense | 2.9 | 2.29 | 2.14 | 4.75 | 10.77 | Upgrade
|
| Earnings From Continuing Operations | 4.9 | 4 | 4.84 | 24.94 | 60.54 | Upgrade
|
| Net Income | 4.9 | 4 | 4.84 | 24.94 | 60.54 | Upgrade
|
| Net Income to Common | 4.9 | 4 | 4.84 | 24.94 | 60.54 | Upgrade
|
| Net Income Growth | 22.56% | -17.31% | -80.61% | -58.81% | -17.61% | Upgrade
|
| Shares Outstanding (Basic) | - | 10 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | - | 10 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | - | -8.49% | -1.40% | 4.59% | -3.35% | Upgrade
|
| EPS (Basic) | - | 0.39 | 0.43 | 2.20 | 5.58 | Upgrade
|
| EPS (Diluted) | - | 0.39 | 0.43 | 2.20 | 5.57 | Upgrade
|
| EPS Growth | - | -9.42% | -80.44% | -60.53% | -14.70% | Upgrade
|
| Free Cash Flow | - | 13.45 | 22.71 | 40.24 | 64.07 | Upgrade
|
| Free Cash Flow Per Share | - | 1.31 | 2.02 | 3.54 | 5.89 | Upgrade
|
| Gross Margin | 45.74% | 46.44% | 44.00% | 46.59% | 53.64% | Upgrade
|
| Operating Margin | 6.39% | 12.86% | 7.76% | 20.19% | 37.84% | Upgrade
|
| Profit Margin | 2.90% | 2.58% | 3.70% | 16.31% | 32.67% | Upgrade
|
| Free Cash Flow Margin | - | 8.68% | 17.39% | 26.32% | 34.57% | Upgrade
|
| EBITDA | 20.31 | 29.45 | 23.29 | 40.5 | 77.98 | Upgrade
|
| EBITDA Margin | 12.02% | 19.00% | 17.82% | 26.49% | 42.08% | Upgrade
|
| D&A For EBITDA | 9.51 | 9.51 | 13.15 | 9.63 | 7.87 | Upgrade
|
| EBIT | 10.8 | 19.93 | 10.14 | 30.87 | 70.12 | Upgrade
|
| EBIT Margin | 6.39% | 12.86% | 7.76% | 20.19% | 37.84% | Upgrade
|
| Effective Tax Rate | 37.18% | 36.38% | 30.70% | 15.99% | 15.10% | Upgrade
|
| Revenue as Reported | 169 | 154.95 | 130.65 | 152.9 | 185.32 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.